A study funded by drugmaker Johnson & Johnson indicates its experimental psoriasis medicine works better than a rival drug that dominates the market for biologic drugs for immune disorders. The J&J drug, guselkumab, is now in its final stage of patient testing and in a couple of years likely will join other recent treatments that offer big improvements for the millions of patients with the common, painful skin disorder.